Cargando…
Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386738/ https://www.ncbi.nlm.nih.gov/pubmed/35992228 http://dx.doi.org/10.2147/TCRM.S363404 |
_version_ | 1784769878081667072 |
---|---|
author | Wang, Zhuoyue Li, Hui Kang, Yimin Liu, Yanlong Shan, Ligang Wang, Fan |
author_facet | Wang, Zhuoyue Li, Hui Kang, Yimin Liu, Yanlong Shan, Ligang Wang, Fan |
author_sort | Wang, Zhuoyue |
collection | PubMed |
description | PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs with respect to the digestive system. Several meta-analyses have compared the risks of digestive side effects of SSRIs and other antidepressants. We aimed to compare the risks of various SSRIs (fluoxetine, escitalopram, citalopram, paroxetine, and sertraline) for adverse reactions of the digestive system. METHODS: Systematic searches returned 30 randomized controlled trials (n = 5004) of five antidepressants and placebos. RESULTS: Fluoxetine had the lowest probability of digestive side effects, ranking fifth at 0.548. Sertraline had the highest probability of digestive side effects, with a probability of 0.611. For gastrointestinal tolerability, escitalopram was better than paroxetine (odds ratio [OR] =0.62, 95% confidence interval [CI] 0.43–0.87) and sertraline (OR=0.56, 95% CI 0.32–0.99). CONCLUSION: Fluoxetine exhibited distinct advantages compared to other SSRIs, while sertraline had the greatest likelihood of digestive system side effects. These findings will help doctors understand the relative advantages of various antidepressants. |
format | Online Article Text |
id | pubmed-9386738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93867382022-08-19 Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis Wang, Zhuoyue Li, Hui Kang, Yimin Liu, Yanlong Shan, Ligang Wang, Fan Ther Clin Risk Manag Review PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs with respect to the digestive system. Several meta-analyses have compared the risks of digestive side effects of SSRIs and other antidepressants. We aimed to compare the risks of various SSRIs (fluoxetine, escitalopram, citalopram, paroxetine, and sertraline) for adverse reactions of the digestive system. METHODS: Systematic searches returned 30 randomized controlled trials (n = 5004) of five antidepressants and placebos. RESULTS: Fluoxetine had the lowest probability of digestive side effects, ranking fifth at 0.548. Sertraline had the highest probability of digestive side effects, with a probability of 0.611. For gastrointestinal tolerability, escitalopram was better than paroxetine (odds ratio [OR] =0.62, 95% confidence interval [CI] 0.43–0.87) and sertraline (OR=0.56, 95% CI 0.32–0.99). CONCLUSION: Fluoxetine exhibited distinct advantages compared to other SSRIs, while sertraline had the greatest likelihood of digestive system side effects. These findings will help doctors understand the relative advantages of various antidepressants. Dove 2022-08-13 /pmc/articles/PMC9386738/ /pubmed/35992228 http://dx.doi.org/10.2147/TCRM.S363404 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Wang, Zhuoyue Li, Hui Kang, Yimin Liu, Yanlong Shan, Ligang Wang, Fan Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title | Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title_full | Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title_fullStr | Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title_full_unstemmed | Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title_short | Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis |
title_sort | risks of digestive system side-effects of selective serotonin reuptake inhibitors in patients with depression: a network meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386738/ https://www.ncbi.nlm.nih.gov/pubmed/35992228 http://dx.doi.org/10.2147/TCRM.S363404 |
work_keys_str_mv | AT wangzhuoyue risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis AT lihui risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis AT kangyimin risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis AT liuyanlong risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis AT shanligang risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis AT wangfan risksofdigestivesystemsideeffectsofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionanetworkmetaanalysis |